Objective To analyse fibroid vascularisation measured with threedimensional (3D) power Doppler in relation to absolute fibroid volume change during 12 months of follow up and in relation to fibroid growth rate per year.
Introduction
Uterine fibroids are a common problem in women and cause a major public health-care burden. [1] [2] [3] Various known and unknown factors may affect fibroid growth. 4 Effective treatment strategies and factors predicting fibroid growth or regression are limited.
There is a large variation in changes in fibroid growth; fibroids in one woman may grow at different rates and up to one-fifth of fibroids regress spontaneously in premenopausal women. [5] [6] [7] [8] Determining growth potential of a distinct fibroid would profit clinical decision making. Potential fibroid growth is particularly relevant in women with limited symptoms and for women considering a (future) pregnancy. Currently there are no strong predictors for fibroid growth that can be used in daily practice.
Angiogenic growth factors play an important role in mechanisms of fibroid pathophysiology, including abnormal vasculature and fibroid growth. 9 The pathophysiology is complex and several hypotheses are made including hypoxia to stimulate angiogenesis and the formation of a fibroid capsule facilitating fibroid growth. Most fibroids have a typical vascular (pseudo)capsule that is an anatomically distinct structure surrounding the fibroid and has its own gene expression profile 10 and rich vascular network. 11, 12 Fibroid vasculature and the pseudo capsule can be visualised using colour Doppler or power Doppler ultrasound.
Three-dimensional (3D) power Doppler (PD) imaging is frequently used to assess the vascularity of a volume/ organ. 3D PD is reported as a reproducible technique in the assessment of fibroids 13, 14 and it has been used to measure vascularisation after gonadotrophin-releasing hormone analogues and ulipristal acetate therapy. 15, 16 It has not yet been studied in relation to fibroid growth. Our hypothesis is that highly vascularised fibroids grow faster than poorly vascularised fibroids and that we are able to use 3D PD to predict fibroid growth rate. The aim of this study is to analyse absolute fibroid growth and fibroid growth rate during 1-year treatment-free follow up in relation to fibroid vascularisation at baseline using 3D PD ultrasound.
Methods

Study design
A prospective cohort study was performed between March 2012 and March 2014 at our outpatient clinic, Department of Gynaecology and Obstetrics, VU University Medical Centre (tertiary referral centre for fibroids), Amsterdam. All premenopausal women diagnosed with a maximum of two fibroids without the use of any (local) hormonal drug therapy were consecutively asked to participate in the study and included. Patients were followed at baseline, 3, 6 and 12 months. Exclusion criteria were fibroids >8 cm (there was no minimum size), more than two fibroids, adenomyosis, pregnancy and (local or systemic) hormonal or surgical therapy. A maximum of two fibroids was chosen (of which the largest was measured) to avoid any risk of mixing measurements of fibroids in the same patient during follow up. The study was listed in the Dutch Trial Register; number NTR3349 and approved by the ethics board of the VU University Medical Centre.
Ultrasound and machine settings
Two-and three-dimensional sonography including PD ( Figure 1 ) were performed at baseline, 3, 6 and 12 months using the Accuvix V10 ultrasound machine (Samsung-Medison, Seoul, South Korea). All volumes were recorded by an experienced examiner (LLN) in a standardised way using a 3D vaginal probe (5-8 MHz) as previously published. 13, 14, 17, 18 Settings of PD were chosen to achieve maximum sensitivity for detecting small vessels without background noise or Doppler artefacts; frequency 5-8 MHz, Gain fixed at 50 dB, pulse repetition frequency 0.60 kHz, Wall motion filter low. Size, location and subjective impression of vascularisation of the fibroid were noted and drawn schematically to ensure correct follow up.
Off-line evaluation of the 3D volumes All stored volumes were evaluated with VOCAL software, Sonoview Pro-1.6.2 (Samsung-Medison). 3D sweep quality was scored on a Likert scale of 1-5 for different ultrasound entities, 1 point for each entity (1. contrast, sharpness, brightness, 2. visibility of fibroid (border), 3. penetration depth, 4. total fibroid visible in sweep, 5. movement artefacts). Volume and Vascular Index (VI) were calculated using the manual contour mode in VOCAL (Virtual Organ Computer-aided AnaLysis). Fibroid contours were drawn in six consecutive planes using a 30°rotation step. Power Doppler indices were then automatically calculated using the histogram function. Fibroid contours measured did not contain the capsule. The fibroid capsule was measured separately. 14 The VI represents the proportion of blood vessels within the tissue (number of colour voxels divided by the total number of both colour and grey voxels).
Statistical analysis
All analyses were performed using SPSS Statistics 22.0 software package (IBM, New York, NY, USA).
To analyse the relationship between vascularisation at baseline and absolute fibroid volume change over 12 months of follow-up linear mixed model analyses for repeated measurements were used. Mixed model analysis was used to take into account the correlation between the repeated measures within the women. Besides the relationship on average over time, also the relationship with fibroid volume at the different time-points was assessed. For the latter, time was added to the analyses as a categorical variable represented by dummy variables. In addition, the same analyses were performed for the capsule of the fibroid. All analyses were adjusted for fibroid volume at baseline and second for age, parity, race, fibroid location and number of fibroids.
Additionally, the relationship between VI at baseline and fibroid growth rate per year was analysed with linear regression analysis. Fibroid growth rate per year was calculated as the difference between fibroid volume at 12 months and fibroid volume at baseline expressed as a percentage of baseline fibroid volume. Besides a crude analysis, analyses were also adjusted for age, race, parity, fibroid location and number of fibroids. A P < 0.05 was considered statistically significant.
Results
Patients
Of the 436 women visiting the outpatient clinic because of fibroid-related symptoms, 66 premenopausal women with a maximum of two fibroids without the use of hormonal therapy could be analysed. The majority of women already used medical therapy, had a high number of fibroids, fibroids only visible with abdominal probe, had no fibroids, were diagnosed with adenomyosis, started drug therapy or received an operation within 3 months, were postmenopausal (fewer than five women) or not willing to participate (fewer than five women). The possibility of starting medical or surgical treatment at follow up was discussed with all women. Two women used Cyklokapron (tranexamic acid) during heavy menstrual blood loss. Median follow up time was 11.7 months (range 2.3-28.4 months). Seven women chose therapy after 3 months of follow up, 13 women could be followed for 6-9 months and 41 were followed for 12 months or more. Twenty-seven women had more than one fibroid. Mean age was 42.8 years (SD: 7.2). Median parity was 1 (range 0-4). Mean Body Mass Index was 23.7 (SD: 3.39). Patients were referred to our outpatient clinic mostly because of possible fibroid-related symptoms; heavy menstrual bleeding 28.8%, bulk symptoms or pain 28.8%, no fibroid-related symptoms 21.2%, infertility 3% and a combination of symptoms 18.1%. Forty-seven percent of the women were north European. 15 women had 17 submucosal fibroids of which ten were FIGO PALM-COIN classification type 5 fibroids; submucosal reaching serosa. 19 Median fibroid diameter was 4.0 cm (range 1.3-8.0 cm).
Absolute fibroid volume change over 1 year
The vast majority of 3D sweeps were of sufficient or good quality (94.3%). Only in 1.4% of 3D sweeps was quality insufficient for proper VI assessment, and these were excluded, in all of these images it concerned a large fibroid. Table 1 Fibroid growth rate per year Regarding growth rate per year we excluded three extreme values (i.e. more than 500% increase or decrease) from the analyses. The average growth rate per year was 8.98% (minimum value: À96%, maximum value: 271%). Fibroid growth rate per year was 10.5% (À12.6 to 57.7%) for highly vascularised fibroids and À8.1% (À51.9 to 39.3%) in fibroids with low vascularity at baseline.
Vascularisation as predictor for fibroid growth Table 2 shows the results of the linear mixed model analyses. Although the fibroid volume distribution was skewed to the right, the residuals of the linear mixed model analyses were normally distributed so no transformation was performed. The VI ranged from 0 to 18% (proportion of blood vessels within the fibroid). VI at baseline was significantly associated with fibroid volume at 12 months, also after correction for fibroid volume at baseline. Additional adjustment for potential confounders slightly attenuated all relationships. The results indicate that an increase of 1% in VI at baseline was associated with a 7.00 cm 3 larger fibroid volume at 12 months. VI of the capsule at baseline was not significantly related to fibroid volume (Table 2) . Fibroid volume at 12 months was also associated with baseline fibroid volume (crude regression coefficient 1.46, 95% CI: 1.29-1.64; P < 0.001; adjusted regression coefficient 1.45, 95% CI: 1.24-1.66; P < 0.001).
After excluding an extreme value (i.e. >5 SD above the mean), VI at baseline was significantly associated with growth rate per year. The crude regression coefficient was 5.30 (95% CI: 1.82-8.95; P = 0.04). Adjusting for potential confounders slightly attenuated this result (adjusted regression coefficient was 4.57 (95% CI: 0.11-9.03; P = 0.045).
In an additional analysis, VI measured at baseline was divided into a low VI group (under the median VI at baseline) and a high VI group (above the median VI at baseline). Figure 2 shows the development of fibroid volume over time for the two groups. Volume of the highly vascularised fibroids increased faster than for poorly vascularised fibroids. Besides that, we also divided baseline volume into two groups based on the median and Figure 3 shows the development of fibroid volume over time for these two groups.
Discussion
Main findings
Baseline fibroid vascularisation measured with 3D PD was significantly related to fibroid volume at 12 months and fibroid growth rate as a % of volume at baseline over 1 year. Fibroid volume increase was larger in highly vascularised fibroids (also after correction for baseline fibroid volume and other confounders). VI of the fibroid capsule at baseline was not related to fibroid volume at 12 months.
Strengths and limitations
Patient selection was carefully designed to obtain a homogeneous group of patients and to observe natural behaviour of fibroids. Patients included had a maximum of two fibroids to allow proper follow up of fibroid measurements and were all included consecutively to reduce the risk of selection bias. Since attenuation can effect 3D PD, 20 a maximum fibroid size of 8 cm was chosen to avoid large affects due to attenuation. Still, it cannot be excluded that some fibroids could have been erroneously classified into the low or high VI group. On the other hand, only five fibroids were 8 cm in largest diameter and in only 1% of the 3D volumes could VI not be calculated due to poor quality. Before the present study was conducted we defined our optimal method for volume and VI assessment and demonstrated our method for measuring fibroid volume and used vascular indices to be highly reproducible in fibroids. 14 We were able to follow up 88.5% of our patients at 1 year and all repeated measurements were executed by the same *Interquartile range was used. **Type of fibroid was classified using the FIGO PALM-COIN classification. FIGO types 0-2 were subdivided as submucosal, types 3-5 as intramural and types 6-8 as subserosal. ***VI is the vascular index measured with VOCAL. The VI represents the proportion of blood vessels within the fibroid. VI measured at baseline was divided into a low VI group (under the median VI at baseline) and a high VI group (above the median VI at baseline. ****Fibroids were categorised into fibroids that increased in volume over 1 year, stayed unchanged or decreased over 1 year.
sonographer on the same machine using the same settings.
Another strength is that we adjusted for potential confounders; fibroid volume at baseline, age, parity, race, fibroid location and number of fibroids. Due to the limited sample size we were not able to correct for many other potential confounding factors such as smoking habits or diet. 21, 22 We did not evaluate fibroid localisation in relation to the large uterine vessels. This could also be interesting in the future. Given the fact that we included a selective group of women without therapy and with a limited number of fibroids, our data cannot be extrapolated to women receiving therapy or with an extensive number of fibroids. Also, this group of women might be relatively asymptomatic as they have not chosen medical or surgical treatment over these 12 months.
Interpretation
Angiogenesis and vascularisation are considered crucial factors in fibroid development and growth. 9, 23 Several studies using contrast magnetic resonance imaging reported a reduced blood flow in fibroids compared to its surrounding myometrium. 24, 25 Differences between uteri with and without fibroids have been studied using 2D colour Doppler. Fibroid uteri showed an increased blood velocity, a decreased resistance index and a decreased pulsatility index in their uterine arteries. 26, 27 Fibroid vascularisation has been compared to its surrounding myometrium and fibroid growth has been followed over time; 7, 21 however, only a few studies reported on both vascularisation and growth in fibroids. 28, 29 Tsuda et al. 30 studied fibroid volume and colour Doppler and reported a correlation between a low uterine artery pulsatility index and growth. A low uterine artery pulsatility index suggests greater blood flow to the fibroid facilitating growth and resulting in more vascularised fibroids. A few studies assessed fibroid volume and VIs after treatment. Czuczwar et al. 16 reported a decrease in fibroid volume and VIs after 3 months of ulipristal therapy. In the study by Chia et al. 15 2 months of gonadotrophin-releasing hormone analogue therapy did not change vascular indices (21 women), while fibroid volume decreased. Using 3D power Doppler ultrasound the present study confirmed the association between vascularisation of the fibroid and fibroid growth. Methods of recording a 3D PD volume, calculating fibroid volume and vascular assessment were similar in the present study as reported in other studies. [13] [14] [15] [16] In 3D PD there are several factors influencing PD indices which should be considered. VI results are dependent on distance between the examined tissue and the probe, 31 which is a basic limitation of the method. Several techniques like spatio-temporal image correlation highdefinition flow technology and fractional moving blood volume are reported to minimise this effect. 19, 32, 33 Another influence on PD indices reported is the cardiac cycle, which may vary between systole and diastole. 30, [34] [35] [36] In fibroids this could not be confirmed (Nieuwenhuis et al, submitted). The capsule of the fibroid surrounds the fibroid and at the same time can be seen as a different entity. It has been a subject of interest and has been studied from different perspectives using different techniques (histopathological, immunohistochemical, [angiogenic] Table 2 . Association between fibroid VI* at baseline and capsule VI at baseline with fibroid volume over time (n = 66) VI** Crude*** P value 95% CI Adjusted**** P value 95% CI Adjusted**** *VI is the number of colour voxels divided by the total number of both colour and grey voxels, representing the proportion of blood vessels within the tissue (fibroid or fibroids capsule). **Fibroid volume and VI was measured with VOCAL software; after fibroid volume acquisition using the manual contour mode and for the capsule the shell mode, VI was automatically calculated with the 'histogram' function. ***Analyses were performed using linear mixed model analysis for repeated measurements. Crude and adjusted regression coefficients are listed (with their corresponding P values and 95% confidence intervals), n = 66. ****Adjusted for fibroid volume at baseline. *****Additionally adjusted for age, parity, race, fibroid location and number of fibroids. ******At baseline, 3 and 6 months there was also no significant association.
gene expression, growth factors, neurotransmitters, imaging techniques). [9] [10] [11] [12] 23, 37, 38 In this study no correlation was found between fibroid capsule vascularisation and fibroid growth. An explanation might be that most fibroids have a vascular capsule and therefore it is less discriminative as a predictor for fibroid growth. Another explanation can be that the capsule is more comparable to the surrounding myometrium than to the fibroid. 39 To our knowledge the capsule has never been studied with 3D PD ultrasound in relation to growth.
Several studies followed women with fibroids over time and reported about fibroid growth (rate). [5] [6] [7] 30 Our results are similar to these studies. All studies demonstrate that fibroids can spontaneously decrease or grow over time.
Growth rates in our study are comparable to those found by Peddada et al. 7 They compared fibroid growth rate in black women and white women and reported that the only factor affecting growth rate was the number of fibroids, which is similar to our result; solitary fibroids tend to grow faster than multiple ones. Mavrelos et al. 6 found type of fibroid to be of influence on growth rate. Intramural fibroids grew faster than subserosal and submucosal fibroids, we found similar results. They also found that fibroids <2 cm grew faster than larger ones. Age, parity and number of fibroids were not of influence. Unexpectedly, we found in women aged <35 years that the majority of fibroids decreased over time; however, this was not corrected for possible confounders, possibly these were, for example, mainly smaller fibroids in this age group. We found, besides vascularisation, size at presentation and number of fibroids to be of influence on fibroid growth rate.
Conclusion
The current study underlines our hypothesis that highly vascularised fibroids tend to grow faster than poorly vascularised fibroids. Determining the growth potential of an individual fibroid will benefit clinical decision making. Our conclusions are limited to women with fibroids <8 cm not receiving therapy. The included group of women with limited symptoms and with small to intermediate fibroids is a challenging group as we do not know whether it is beneficial to offer these women therapy or not. This depends on the growth potential of fibroids. When growth potential is high, follow up is needed and therapy could be considered to prevent larger fibroids that are less likely to be treatable by minimally invasive options. However, if the growth potential is low, unnecessary therapies could be prevented and follow up could be diminished. Our results should be confirmed in future studies, preferably with longer follow up, and clear cut-off levels need to be established before the current technique can be implemented in daily practice. Besides the potential of predicting growth, 3D PD may also be useful in predicting the effect of hormonal or minimally invasive therapy but this needs to be established in future studies. The same accounts for 3D PD evaluation in the prediction of the effectiveness of minimally invasive techniques. [40] [41] [42] [43] Given the lower costs and better accessibility of 3D PD compared with magnetic resonance imaging, 3D PD can be seen as having strong potential for implementation in clinical practice provided that future studies confirm the current results.
In conclusion, baseline vascularisation (VI) measured with 3D PD was associated with fibroid volume at 12 months and with fibroid growth rate per year. Relation fibroid vascularisation and fibroid growth. VI is the number of colour voxels divided by the total number of both colour and grey voxels, representing the proportion of blood vessels within the tissue. VI was measured with 3D PD ultrasound and calculated with VOCAL software. After fibroid volume acquisition (using the manual contour mode), VI was automatically calculated with the 'histogram' function. VI measured at baseline was split into a low VI group (VI under the median VI at baseline) and a high VI group (VI above the median VI at baseline). Total group n = 66. In the mixed model analyses, vascularisation was significantly correlated with fibroid growth, even when we corrected for fibroid volume (not performed in figure) .
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